Revvity Inc. stock falls 1.87% and underperforms market competitors

3 articles · Updated · MarketWatch · Apr 28

Revvity Inc. shares closed at $85.18 on Tuesday, 28% below its 52-week high of $118.30 set in January.
The stock's decline outpaced Danaher Corp., IDEXX Laboratories, and Agilent Technologies, as major indices like the S&P 500 and Dow Jones also fell.
Trading volume matched its 50-day average at 1.1 million shares, reflecting broader market weakness during the session.

Why is Revvity lagging while the broader biotech sector is booming?

Analysts are split on Revvity's valuation. Is it a bargain or overpriced?

Is the market overreacting to Revvity's conservative growth forecast?

Can Revvity's new AI platform reignite its sluggish life sciences growth?

Can Revvity's leadership restore investor trust amid shareholder activism?